Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDGFA-associated protein 1 (PDAP1)
- Target
- PDAP1
- Molecular classification
- Other (phosphoprotein; not a classical receptor, enzyme, transporter, ion channel, or transcription factor)
01
Overview
PDGFA-associated protein 1 (PDAP1) is a ubiquitously expressed, highly conserved, 28 kDa heat- and acid-stable phosphoprotein that modulates growth factor signaling, particularly by enhancing the mitogenic effects of platelet-derived growth factor alpha (PDGFA) on fibroblast proliferation and inhibiting PDGFB-driven growth. Functionally, PDAP1 promotes cell proliferation, migration, and invasion in multiple cellular contexts, notably contributing to the initiation and progression of colorectal cancer via EGFR-MAPK pathway activation. Preclinical and multi-omics studies implicate PDAP1 as a prognostic marker and a potential therapeutic target, with its overexpression correlating with poor survival in cancer patients. Aside from proliferative roles, PDAP1 is involved in immune regulation, supporting mature B cell survival and antibody diversification. No approved drugs currently target PDAP1, but genetic silencing experiments demonstrate its potential utility in cancer therapy.
- Other names
- PDAP128 kDa heat- and acid-stable phosphoproteinHASPP28PAPPAP1PDGF-associated proteinPDGFA-associated protein 1
02
Mechanism of action
Not established. Preclinical data suggest that silencing PDAP1 hinders tumor cell growth and invasion, likely by interfering with EGFR-MAPK pathway activation
03
Biological functions
Upregulates PDGFA-stimulated cell growth in fibroblastsDownregulates mitogenicity of PDGFBInteracts with EGFR and facilitates activation of the EGFR-MAPK-FRA-1 signaling axisRegulates cell proliferation, migration, invasion, and metastasisInvolved in mucosal restitution and carcinogenesis in the context of inflammatory bowel disease and colorectal cancerProtects mature B lymphocytes from stress-induced cell deathPromotes antibody gene diversification
04
Disease associations
Cancer (notably colorectal cancer and glioma)Inflammation (particularly colitis-associated cancer)Immune-related roles (e.g., B cell stress response, antibody diversification)
05
Safety considerations
Not well-characterized; as of current knowledge, no specific safety concerns or therapeutic challenges have been established. The consequence of PDAP1 loss includes impaired mucosal restitution, which could pose a challenge for tissue repair in inflammatory conditions
06
Interacting drugs
None directly identified in current public datasets or literature. PDAP1 is a proposed/novel target for therapy in colorectal cancer but specific drug interactions are not reported as of this writing
07
Biomarkers
PDAP1 overexpression serves as a potential biomarker for poor prognosis in colorectal cancer
Beyond the preview
Go deeper on PDGFA-associated protein 1 (PDAP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDGFA-associated protein 1 (PDAP1).